Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV vaccine acceptability and compliance study in screening-age women
NL-OMON44098Phase 4Withdrawn
- Sponsor
- Vrije University Medical Center
- Start
- May 2016
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection, Cervical Cancer (CC), anogenital warts and 1 more, sponsored by Vrije University Medical Center. Primary endpoint: Vaccine uptake. Planned start May 2016; status: withdrawn.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infectionCervical Cancer (CC)anogenital wartsGenital Premalignant Lesion
Beyond the preview
Go deeper on NL-OMON44098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44098.